Programme
Contents |
Digoxin is a specific inhibitor of the Na+,K+-pump and is used to treat patients with severe heart failure. In these patients, digoxin binds and blocks ∼13% of Na+,K+-pumps in skeletal muscle and exacerbates muscle K+ loss during exercise. Furthermore in heart failure patients there is no compensatory upregulation of Na+,K+-pump with chronic digitalisation. We have shown that exercise impairs Na+,K+-pump activity, whilst in isolated rat muscles, Na+,K+-pump inhibition leads to early muscle fatigue (Clausen, 2003). Hence, Na+,K+-pump function is likely to be important for skeletal muscle performance. However, the effects of digoxin on Na+,K+-pump content, activity, protein abundance or isoform expression in skeletal muscle of healthy individuals are unknown and were investigated here.
Ten active, but not well-trained healthy volunteers (9 M, 1 F) gave written informed consent. Exercise tests were performed after taking digoxin (DIG, 0.25 mg.d-1) or a placebo (CON) for 14 d, in a randomised, counterbalanced, cross-over, double blind design, with trials separated by 4 weeks. Subjects performed incremental cycle ergometer exercise to measure VO2peak and to determine 33, 67 and 90% VO2peak work rates. On d 14 subjects completed 10 min cycling at each of 33% and 67% VO2peak, then to fatigue at 90% VO2peak. Muscle biopsies taken at rest, after 67%, 90%VO2 peak and 3 h recovery were analysed for Na+,K+-pump content (3H-ouabain binding site), maximal activity (3-O-methyfluorescein phosphatase, 3-O-MFPase), isoform protein abundance and mRNA expression. The Na+, K+-pump isoform (α1-α3, β1-β3) protein contents were measured on muscle extracts, using specific antibodies and western blotting, with isoform mRNA expression determined with real-time RT-PCR analysis.
Serum digoxin was 0.7±0.2 nM at d 13 and 0.8±0.2 nM at d 14 (Mean±SD). Despite this, muscle maximal Na+,K+-pump activity was unchanged by digoxin. However, Na+,K+-pump activity was decreased after exercise, by 13% and 11% at fatigue and 3 h post-exercise, compared to rest, respectively (P<0.05). Furthermore, there was no change in the Na+,K+-pump content with either digoxin or exercise (Rest Digoxin 373±95, Rest Placebo 368±75 pmol.g wet weight-1). No significant change occurred with digoxin for mRNA expression of any of the α1, α2, α3, β1, or β3 isoforms. However, digoxin increased the mRNA expression of the total α mRNA (sum of α1, α2, α3) and the total β mRNA (sum of β1 and β3) at rest by 1.9- and 1.8-fold, respectively (P<0.05), suggesting an effect of digoxin on Na+,K+-pump gene expression. An exercise effect was observed on α3 mRNA expression, being 2.1-and 2.4-fold higher at 3 h post-exercise than during exercise at 67% VO2peak and fatigue, respectively (P<0.05). Similarly, β3 mRNA expression at 3 h post-exercise was increased by 1.8-, 1.4- and 1.6-fold, compared to rest, 67% VO2peak exercise and fatigue, respectively (P<0.05). Digoxin did not alter the protein abundance of any isoform in resting muscle. However, at 3 h post-exercise, the protein abundance was greater with digoxin than in placebo for both α2 and β3 (P<0.05). The β1 protein expression was increased at 3 h post-exercise by 2.2-and 1.5-fold compared to during exercise at 67% VO2peak and fatigue, respectively (P<0.05). Similarly, β3 protein expression was increased at 67% VO2peak and 3 h post-exercise compared to rest, by 1.5-and 1.6-fold, respectively (P<0.05).
In summary, digoxin treatment had only minimal effects on muscle Na+,K+-pumps in healthy individuals. Whilst Na+,K+-pump content, activity or isoform protein expression at rest were unchanged, the subunit total mRNA expression was increased with digoxin and a greater post-exercise protein abundance was found with digoxin for α2 and β3. The lack of reduction in pumps with digitalisation in healthy muscles suggests either that pumps were upregulated and/or that digoxin dissociation was increased.
Clausen, T. (2003) Physiolgical Reviews 83, 1269-324.